MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).
Paul Gerard Guy Richardson
Consultant or Advisory Role - Celgene; Johnson & Johnson; Millennium; Novartis
Craig C. Hofmeister
Consultant or Advisory Role - Celgene
Research Funding - Celgene; Merck; Millennium; Oncolytics Biotech
David Samuel DiCapua Siegel
Honoraria - Celgene; Merck; Millennium; Onyx
Sagar Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Johnson & Johnson; Millennium; Novartis; Onyx; Sanofi
Jacob Laubach
No relevant relationships to disclose
Yvonne Adeduni Efebera
No relevant relationships to disclose
David H. Vesole
Consultant or Advisory Role - Celgene; Onyx
Honoraria - Celgene; Millennium; Onyx
Ajay K. Nooka
No relevant relationships to disclose
Jacalyn Rosenblatt
No relevant relationships to disclose
Noopur S. Raje
Consultant or Advisory Role - Amgen; Celgene; Millennium; Onyx
Research Funding - Acetylon Pharmaceuticals; Lilly
Mohamed H. Zaki
Research Funding - Celgene
Ye Hua
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Sheetal Shah
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Jianming Wang
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Kenneth Carl Anderson
Consultant or Advisory Role - Celgene; Gilead Sciences; Onyx; Sanofi
Other Remuneration - Acetylon Pharmaceuticals; OncoPep